NAD+ (Nicotinamide Adenine Dinucleotide) [Nasal Spray]

Description

What is NAD+ Nasal Spray?

NAD+ is an endogenous dinucleotide coenzyme present in virtually all living cells and is among the most functionally central molecules in mammalian biochemistry. It consists of two nucleotides, adenosine monophosphate (AMP) and nicotinamide mononucleotide (NMN), joined by a pyrophosphate linkage. NAD+ is the oxidized form of the NAD+/NADH redox pair: NAD+ acts as an electron acceptor, becoming reduced to NADH during catabolic reactions; NADH then donates electrons to the electron transport chain for ATP synthesis via oxidative phosphorylation. Beyond its role in redox reactions, NAD+ also serves as a consumable co-substrate for enzymes such as sirtuins (SIRT1-7), PARPs, and CD38/CD157, which cleave and consume NAD+ during catalysis.

NAD+ is chemically and pharmacologically distinct from its reduced form, NADH (CAS 58-68-4; MW 665.4 g/mol), and from the phosphorylated analog NADP+ (CAS 53-59-8; MW 744.4 g/mol; PubChem CID 5885).  It is also distinct from its biosynthetic precursors, nicotinamide mononucleotide (NMN; CAS 1094-61-7; MW 334.22 g/mol) and nicotinamide riboside (NR; CAS 1341-23-7; MW 255.25 g/mol). The research-grade NAD+ nasal spray supplied by RCDbio supplies the oxidized NAD+ species directly, not a precursor that requires intracellular conversion to NAD+. This distinction has implications for intracellular uptake: while NMN and NR enter cells via specific transporters and are enzymatically converted to NAD+ intracellularly, exogenous NAD+ itself does not readily cross intact cell membranes, and its bioavailability following any route of administration depends on extracellular enzymatic degradation, transporter-mediated uptake of degradation products, and intracellular resynthesis. Researchers selecting between direct NAD+ and precursor formulations should confirm which form is appropriate for their specific assay system.

Cellular NAD+ levels decline measurably during aging in multiple tissues, including the human brain, and this age-associated decline has been linked to impaired mitochondrial function, reduced SIRT1 activity, increased PARP-mediated NAD+ consumption following DNA damage accumulation, elevated CD38 expression with aging, and the onset of metabolic, neurodegenerative, and cardiovascular age-related disease states [Stromland et al., 2021; PMID 34509469]. The primary NAD+ biosynthetic enzyme NAMPT (nicotinamide phosphoribosyltransferase), which catalyzes the rate-limiting step of the salvage pathway from nicotinamide, declines with age in several tissues, further limiting the capacity for intracellular NAD+ regeneration.

The nasal spray formulation is investigated as a delivery route in preclinical research contexts, based on evidence of olfactory bulb-mediated and trigeminal nerve-mediated CNS transport for compounds administered intranasally in rodent models. Intranasal delivery is of particular research interest for NAD+ given the age-associated decline of brain NAD+ levels and the blood-brain barrier’s relative impermeability to direct NAD+ transport, making the nose-to-brain route a potentially relevant pathway for CNS NAD+ repletion research [Wong et al., 2024; PMID 38441832].

DISCLAIMER: NAD+ (Nicotinamide Adenine Dinucleotide) Nasal Spray, as supplied by RCDbio is not a dietary supplement and has not been approved by the Food and Drug Administration for human use, veterinary use, consumption, or any therapeutic application via the intranasal route. This product is not intended for human consumption or therapeutic self-administration. It is supplied exclusively for in vitro and preclinical laboratory research purposes. All RCDbio research compounds are for laboratory and research purposes only.

Chemical Properties of NAD+

Property	Details
Product Type	Endogenous Dinucleotide Coenzyme / Hydride-Transfer Redox Cofactor / Sirtuin Co-substrate / PARP Co-substrate / CD38 Substrate / NAD+/NADH Redox Pair Oxidized Form
Product Name	NAD+ (Nicotinamide Adenine Dinucleotide) Nasal Spray
Application	Scientific / Research Use Only
CAS Number	53-84-9
Molar Mass	664.4 g/mol (NAD+, oxidized form, free acid)
Chemical Formula	C21H27N7O14P2
IUPAC Name	[[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
Synonyms	NAD+; NAD; beta-NAD+; beta-Nicotinamide Adenine Dinucleotide (oxidized); Coenzyme I; Diphosphopyridine nucleotide (DPN); Codehydrogenase I; Nadide. Distinct from: NADH (reduced form; CAS 58-68-4); NADP+ (CAS 53-59-8); NMN (CAS 1094-61-7); NR (CAS 1341-23-7).
Physical Form	White to off-white lyophilized powder (compound); supplied as aqueous nasal spray solution.
Solubility	Freely soluble in water (>100 mg/mL); insoluble in most organic solvents
Storage (Lyophilized)	-20°C; sealed container under inert gas (nitrogen or argon); desiccated; light-protected. NAD+ lyophilized powder is hygroscopic and susceptible to oxidative and hydrolytic degradation on exposure to air and moisture.
Storage (Reconstituted / Nasal Spray)	2-8°C; use within 14 days of first actuation; DO NOT FREEZE; protect from light; keep upright; minimize air exposure. The 14-day in-use shelf life reflects the hydrolytic instability of NAD+ in aqueous solution, intermediate between the 7-day GSH shelf life and the 28-day stable peptide shelf life in this range.
PubChem CID	925 (NAD+, oxidized form; beta-nicotinamide adenine dinucleotide; CAS 53-84-9)
Purity	>=98% (HPLC verified, independent third-party laboratory analysis; COA available per batch
WADA Status	NAD+ is not explicitly named on the 2026 WADA Prohibited List. As an endogenous coenzyme universally present in all mammalian cells, it does not fall within the currently named prohibited substance categories. However, WADA’s S0 category (non-approved substances) may apply to formulations of NAD+ labeled “research use only” or “not for human consumption” in a competitive sports context. Researchers operating within WADA Code jurisdictions should verify current status at GlobalDRO.com prior to any use. RCDbio products are for laboratory research purposes only.

How Does NAD+ Work?

NAD+ is unique among the compounds in the RCDbio nasal spray research range in that it is not a peptide, not a peptide analog, and not a receptor agonist in the conventional pharmacological sense. Its biological activity operates through two mechanistically distinct modes: (1) as a hydride-transfer cofactor in oxidation-reduction reactions, cycling between NAD+ and NADH without net consumption; and (2) as a consumed co-substrate for signaling enzymes that cleave the glycosidic bond of NAD+, releasing nicotinamide and ADP-ribose derivatives as products and reducing total cellular NAD+ with each catalytic cycle. The balance between NAD+ biosynthesis (primarily via the NAMPT-mediated salvage pathway) and NAD+ consumption (primarily by PARPs, sirtuins, and CD38) determines cellular NAD+ homeostasis. The following mechanistic observations are from in vitro, preclinical, and human biochemistry data unless otherwise specified.

Redox Cofactor Function: NAD+/NADH Couple and Cellular Energy Metabolism

NAD+ accepts a hydride ion (H⁻) from substrates during catabolic reactions — glycolysis, the TCA cycle, beta-oxidation of fatty acids — becoming reduced to NADH. NADH then donates its electrons to Complex I of the mitochondrial electron transport chain, driving proton pumping and ATP synthesis via oxidative phosphorylation. NAD+ is regenerated from NADH by this process, completing the cycle without net consumption. The NAD+/NADH ratio is a key determinant of cellular metabolic state, with a high NAD+/NADH ratio favoring catabolic (energy-generating) metabolic activity. Disruption of this ratio impairs mitochondrial function, glycolytic efficiency, and ATP production capacity [Griffiths et al., 2020; PMID 32573651].

Sirtuin (SIRT1-7) Co-substrate Activity and Epigenetic Regulation

The sirtuin family of NAD+-dependent protein deacetylases (SIRT1-7) requires NAD+ as a stoichiometric co-substrate, not merely a cofactor,  for catalytic activity. For each deacetylation reaction, one molecule of NAD+ is cleaved to produce nicotinamide and O-acetyl-ADP-ribose, and the target protein’s acetyl group is removed. SIRT1 is the most studied isoform, deacetylating histones (H3K9ac, H4K16ac) to regulate chromatin compaction and gene expression, and non-histone substrates including p53, NF-kB (p65 subunit), FOXO transcription factors, and PGC-1alpha. SIRT1 activation promotes oxidative energy metabolism and inhibits NF-kB-driven inflammatory signaling. SIRT1 inhibits NF-kB signaling directly by deacetylating the p65 subunit, while simultaneously stimulating oxidative energy production via AMPK, PPARalpha, and PGC-1alpha activation [Kauppinen et al., 2013; PMID 23770291]. The dependency of all seven sirtuin isoforms on NAD+ availability means that declining cellular NAD+ directly limits sirtuin activity — a mechanistic link between NAD+ depletion and age-associated epigenetic dysregulation, mitochondrial dysfunction, and inflammatory activation.

PARP Family Co-substrate Activity and DNA Repair

The poly(ADP-ribose) polymerase (PARP) family — particularly PARP1 and PARP2 — consumes NAD+ stoichiometrically during DNA damage repair. Upon detection of DNA single- or double-strand breaks, PARP1 cleaves NAD+ and transfers ADP-ribose units to target proteins (poly-ADP-ribosylation; PARylation), forming PAR chains that recruit DNA repair machinery. Under conditions of excessive DNA damage — such as oxidative stress, UV exposure, or genotoxic insult — PARP hyperactivation can deplete cellular NAD+ reserves faster than the salvage pathway can regenerate them, creating a futile cycle of NAD+ depletion that can trigger cell death via energy failure (parthanatos) or necrosis. The PARP-mediated NAD+ depletion mechanism is a primary driver of NAD+ decline under pathological conditions and an important research target for neuroprotection, ischemia, and aging biology [Griffiths et al., 2020; PMID 32573651].

CD38 and Age-Associated NAD+ Consumption

CD38 is an NAD+ glycohydrolase expressed on immune cells and various other cell types whose expression increases substantially with aging. CD38 hydrolyzes NAD+ to produce cyclic ADP-ribose (cADPR) and ADPR, consuming NAD+ in the process. Elevated CD38 activity in aged tissues is considered a major driver of the age-associated decline in tissue NAD+ levels, alongside reduced NAMPT expression. CD38 knockout mouse studies have demonstrated substantially higher tissue NAD+ levels and improved metabolic function relative to wild-type aged animals, establishing CD38 as a key regulator of NAD+ homeostasis during aging [Stromland et al., 2021; PMID 34509469].

NAD+ Decline in Aging and Neurodegeneration

Tissue NAD+ levels decline measurably during physiological aging in multiple mammalian species, including humans. The mechanisms include: age-associated reduction in NAMPT (rate-limiting enzyme of the salvage pathway), increased PARP activation due to accumulating DNA damage, elevated CD38 expression on immune and stromal cells, and chronic inflammatory NF-kB signaling that suppresses SIRT1. The age-dependent decline in brain NAD+ is of particular research interest given the established dependence of neuronal survival, mitochondrial function, and synaptic integrity on adequate NAD+ availability. Declining NAD+ has been associated with cognitive impairment, increased susceptibility to neurodegeneration, and impaired DNA repair in neuronal preparations [Stromland et al., 2021; PMID 34509469; Braidy et al., 2018; PMID 29634344].

NAD+ Precursors vs. Direct NAD+ Administration

The majority of published research on NAD+ repletion uses precursor molecules — NMN, NR, nicotinamide (NAM), and nicotinic acid (NA) — rather than direct NAD+ administration, because these smaller, more cell-permeable molecules enter cells via specific transporters and are converted to NAD+ intracellularly via the salvage pathway. Direct exogenous NAD+ has limited cell membrane permeability; cellular uptake depends on extracellular hydrolysis to NMN or NR by CD73 or other ecto-nucleotidases, followed by transporter-mediated uptake of the precursor. The research-grade NAD+ nasal spray supplied by RCDbio delivers the NAD+ molecule directly to the nasal mucosa, from which absorption, hydrolysis, and olfactory nerve transport pathways are the subject of ongoing investigation. Researchers should be aware that the intracellular NAD+-elevating effect of administered NAD+ may be mediated by precursor metabolites rather than intact NAD+ uptake.

Intranasal Delivery & Pharmacokinetics

Olfactory Bulb-Mediated CNS Transport

When administered intranasally in preclinical rodent model systems, compounds can access the central nervous system through the olfactory nerve (cranial nerve I) and trigeminal nerve pathways. Olfactory axon-mediated transport through the cribriform plate to the olfactory bulb, and from there to deeper CNS structures, has been characterized for a range of small molecules, peptides, and proteins in rodent preparations [Wong et al., 2024; PMID 38441832]. The blood-brain barrier is substantially impermeable to direct NAD+ transport, making the nose-to-brain route a research-relevant pathway for investigating CNS NAD+ delivery without systemic IV administration. No compound-specific intranasal pharmacokinetic or CNS distribution data for research-grade NAD+ nasal spray have been published as of June 2026.

Molecular Weight and Nasal Mucosal Absorption

NAD+ has a molar mass of 664.4 g/mol (~0.66 kDa). This is substantially larger than small molecule drugs that readily cross the nasal mucosa by passive transcellular diffusion (typically below 500 Da) but smaller than the larger peptides in this range (e.g., tesamorelin at ~5.14 kDa). Nasal mucosal absorption of NAD+ is expected to occur primarily via paracellular transport and potentially via ecto-nucleotidase-mediated hydrolysis to NMN or NR at the mucosal surface, followed by transporter-mediated uptake of the smaller precursor species. The hydrophilic and zwitterionic character of NAD+ at physiological pH limits passive transcellular lipid-bilayer diffusion.

Enzymatic Stability at the Nasal Mucosa

A critical stability consideration unique to NAD+ among compounds in this range is the presence of NAD+-consuming enzymes at the nasal mucosa itself. CD38 is expressed on nasal epithelial and immune cells, and SARM1 (sterile alpha and TIR motif-containing protein 1) is present in neuronal axons accessible via the olfactory nerve. Both enzymes hydrolyze NAD+, potentially reducing the amount of intact NAD+ reaching systemic circulation or CNS targets. Nasal mucosal NADase activity is a meaningful degradation variable that does not apply to peptide compounds in this range. Researchers should design protocols accounting for this extracellular NAD+ consumption pathway.

Compound-Specific Pharmacokinetics

No formal intranasal pharmacokinetic data (Tmax, Cmax, brain NAD+ elevation, or CNS bioavailability) have been published for research-grade NAD+ nasal spray as of June 2026. Published pharmacokinetic data for NAD+ precursors (NMN, NR) via oral routes cannot be directly extrapolated to intranasal NAD+ administration. Researchers should account for the absence of published intranasal NAD+ pharmacokinetic data, the extracellular NADase degradation pathway, and the cell membrane permeability limitation of intact NAD+ when designing laboratory protocols.

Key Research Findings

NAD+ as Essential Redox Metabolite, Sirtuin and PARP Co-substrate, and Therapeutic Target in Aging and Cancer (Review, Biochem Soc Trans, 2020): NAD+ and NADH are essential coupled redox metabolites promoting cellular oxidative metabolic reactions and energy generation through glycolysis and mitochondrial respiration; NAD+-dependent sirtuins regulate gene expression and proteostasis; PARP family enzymes consume NAD+ during DNA repair; NAD+ homeostasis is maintained by multiple regeneration pathways including the NAMPT-mediated salvage pathway; NAD+ levels decline in the human brain and other organs with age, associated with neurodegeneration and age-related disease; cancer cells demonstrate increased dependency on NAD+; NAMPT inhibition is a cancer therapeutic target under investigation [Griffiths et al., 2020; PMID 32573651]

The Balance Between NAD+ Biosynthesis and Consumption in Aging — NAMPT, PARP, CD38, and Cognitive Decline (Review, Mech Ageing Dev, 2021): Cellular NAD+ levels decline during aging in multiple organisms including humans; declining NAD+ has been linked to metabolic disease and cognitive decline; the decline results from imbalance between reduced NAMPT-mediated biosynthesis and increased NAD+ consumption by PARP and CD38 with aging; NAD+ metabolism has emerged as a potential target for age-related disease amelioration; current NAD+ repletion approaches — including precursor supplementation — can halt or reverse progression of some age-related conditions in preclinical model systems [Stromland et al., 2021; PMID 34509469]

NAD+ and Precursors as Therapeutic Targets for Age-Related Degenerative Diseases — Biochemistry, Pharmacokinetics, and Outcomes (Review, Antioxid Redox Signal, 2018): NAD+ is an essential pyridine nucleotide cofactor for oxidative phosphorylation, ATP production, DNA repair, epigenetic gene expression, intracellular calcium signaling, and immunological function; NAD+ depletion occurs via PARP hyperactivation and accelerated CD38 activity; promotion of intracellular NAD+ synthesis is a promising therapeutic strategy for age-associated degenerative disease; NAD+ precursors NMN, NR, NAM, and NA can attenuate NAD+ decline in degenerative disease states with differing efficacy based on their position in the NAD+ anabolic pathway; enhanced NAD+ synthesis promotes protective cell responses [Braidy et al., 2018; PMID 29634344]

All three references are peer-reviewed, mechanistic, and pharmacological reviews of NAD+ biology in human and animal model systems. None characterizes intranasal NAD+ delivery specifically. No published peer-reviewed study has formally characterized the pharmacokinetics, CNS bioavailability, or biological activity of intranasal research-grade NAD+ nasal spray as of June 2026. NAD+ is the only non-peptide compound in the RCDbio nasal spray research range; its mechanisms of action, stability profile, and delivery pharmacology differ fundamentally from the peptide compounds in this series. These observations do not constitute evidence of efficacy or safety for the research-grade nasal spray formulation in any organism.

What are the Potential Research Applications?

In controlled laboratory environments, NAD+ nasal spray has been investigated for the following research applications. These are observed in preclinical and in vitro contexts only and do not constitute claims of efficacy or safety in any organism.

CNS NAD+ Repletion and Neurodegeneration Research

The age-associated decline of brain NAD+ and its link to neurodegeneration make intranasal NAD+ delivery a research-relevant approach for CNS NAD+ repletion studies in preclinical models. Research applications include quantification of brain and olfactory bulb NAD+ levels following intranasal NAD+ administration in rodent preparations, comparison of intranasal NAD+ versus NMN and NR precursor routes for CNS NAD+ elevation, SIRT1 and PARP1 activity assays in neuronal cell preparations under NAD+-depletion and repletion conditions, and Alzheimer’s disease and Parkinson’s disease model preparations investigating NAD+ homeostasis disruption.

Sirtuin Biology and NAD+-Dependent Epigenetic Research

NAD+ is the obligate co-substrate for all seven sirtuin isoforms. Research applications include SIRT1 deacetylase activity assays in cell-free and cellular systems at defined NAD+ concentrations, histone deacetylation and chromatin compaction studies in neuronal or metabolic cell preparations, SIRT1/NF-kB crosstalk investigation in inflammatory model systems, PGC-1alpha-mediated mitochondrial biogenesis studies, and comparative sirtuin isoform activity profiling (SIRT1-7) at varying NAD+ concentrations.

PARP-Mediated DNA Repair and NAD+ Depletion Research

PARP1 and PARP2 consume NAD+ stoichiometrically during DNA repair. Research applications include PARP1 activity assays measuring NAD+ consumption rates under varying DNA damage conditions, parthanatos pathway investigation in neuronal and metabolic cell preparations, NAD+ depletion-rescue protocols in genotoxic stress model systems, PARP inhibitor combination studies characterizing NAD+ conservation mechanisms, and quantification of NAD+ depletion kinetics following DNA strand break induction.

NAD+ Metabolism and CD38 Biology Research

CD38-mediated NAD+ consumption is a primary driver of age-associated NAD+ decline. Research applications include CD38 enzymatic activity assays using NAD+ as substrate in aged versus young tissue preparations, cADPR synthesis characterization, calcium signaling studies downstream of CD38/cADPR pathway activation, and CD38 inhibitor combination experiments to characterize NAD+ conservation in aged tissue model systems.

Intranasal Delivery and NAD+ Pharmacokinetics Research

The intranasal route for NAD+ delivery lacks published pharmacokinetic characterization as of June 2026, creating an open research gap. Research applications include nose-to-brain NAD+ transport characterization in rodent olfactory model preparations, nasal mucosal NADase activity quantification as a degradation variable for intranasal NAD+ delivery, comparison of intranasal NAD+ versus NMN and NR administration for CNS NAD+ elevation, and formulation optimization for pH-stable intranasal NAD+ delivery.

What are the Potential Side Effects?

Researchers in preclinical and in vitro settings have noted the following observations. Long-term safety and toxicity profiles remain incompletely characterized for the research-grade nasal spray formulation.

• No completed human clinical trials for intranasal NAD+ administration: No published peer-reviewed human clinical trials have investigated the safety, tolerability, or pharmacokinetics of NAD+ administered via nasal spray; available human clinical data involves oral NMN and NR precursor supplementation, not direct intranasal NAD+; this data does not transfer directly to the nasal spray route.
• Favorable general safety profile — class-level context: Intravenous NAD+ infusion has been used clinically in some contexts; oral NAD+ precursors (NMN, NR) have been investigated in human clinical studies with generally favorable safety profiles at doses studied; these findings are class-level context for NAD+ biology and do not constitute safety evidence for the research-grade intranasal formulation
• Flushing response (class-level context, relevant at high concentrations): Nicotinic acid (NA), a related NAD+ precursor, causes prostaglandin-mediated flushing; NAD+ itself may produce mild vascular flushing via downstream nicotinamide metabolite production; this potential effect has not been characterized for intranasal administration and is noted as class-level pharmacological context only.
• Nasal mucosal irritation (local administration context): As a charged dinucleotide formulated at physiological pH, NAD+ may produce mild mucosal irritation at high concentrations at the administration site; no published data characterizes the nasal mucosal tolerability of research-grade NAD+ nasal spray
• Enzymatic degradation products at the mucosal surface: CD38-mediated hydrolysis of NAD+ at the nasal mucosa produces cADPR and ADPR, which may have local biological activity in nasal mucosal immune cells; this is a mechanistic consideration for interpreting intranasal NAD+ delivery research data

No human safety or tolerability data has been established for research-grade NAD+ nasal spray via the intranasal route. These observations are derived from experimental systems and class-level clinical context and should not be extrapolated to human or animal outcomes.

Risk & Handling

Handling Precautions

Standard laboratory PPE is required: nitrile gloves, a laboratory coat, and eye protection. The following nasal spray-specific and compound-specific precautions apply:

1. Do not direct the nasal spray actuator toward the face, eyes, or mucous membranes during handling, testing, or transfer. Although NAD+ is an endogenous metabolite universally present in all mammalian cells, the pharmacological activity of high-concentration exogenous NAD+ at the nasal mucosa has not been characterized, and inadvertent intranasal self-exposure at research concentrations should be avoided.
2. Handle the nasal spray solution in a clean laboratory environment. For aliquoting or analytical sampling, use a laminar flow cabinet.
3. The nasal spray solution is an aqueous formulation susceptible to both microbial contamination and hydrolytic degradation. Discard if the solution appears cloudy, discolored, or shows particulate matter, or after 14 days from first actuation, regardless of appearance.
4. Avoid aerosol generation during any manipulation of the nasal spray solution. Monitor solution integrity by UV absorbance (A260/A340 ratio) before research use.

Exposure Risks

Risk Tier: LOW

NAD+ is an endogenous coenzyme universally present in all mammalian cells at micromolar to millimolar concentrations. No acute toxicity has been established for NAD+ at physiological or near-physiological concentrations. No completed human clinical trial data exist specifically for intranasal NAD+ administration. The primary laboratory risks are: use of hydrolytically degraded material producing incorrect experimental results in NAD+-dependent enzyme assays; nasal mucosal CD38-mediated degradation of administered NAD+, confounding delivery research protocols; and osmolarity or pH effects at high spray concentrations. Confirm solution integrity by UV absorbance before each experimental use.

Storage

In-use nasal spray: Store at 2-8°C. Use within 14 days of first actuation. Protect from light. Keep upright. Minimize air exposure at actuation. Discard after 14 days regardless of remaining volume or appearance.

DO NOT FREEZE the ready-to-use nasal spray formulation. Freeze-thaw cycles promote hydrolytic degradation of NAD+ and compromise buffer stability and pH.

Lyophilized bulk stock: Store at -20°C in sealed containers under inert gas (nitrogen or argon), desiccated, light-protected. NAD+ powder is hygroscopic — reseal immediately after each use. Avoid repeated freeze-thaw cycles.

Discard any solution that appears cloudy, discolored, or shows visible particulate matter.

FAQs

Q: How does intranasal NAD+ access CNS targets, and why is this route investigated for NAD+ research?

A: The blood-brain barrier is substantially impermeable to direct NAD+ transport, making systemic IV or oral routes inefficient for elevating brain NAD+ levels directly. The intranasal route bypasses the blood-brain barrier via olfactory and trigeminal nerve-mediated nose-to-brain transport [Wong et al., 2024; PMID 38441832], making it a research-relevant pathway for CNS NAD+ delivery investigation. Researchers should account for the fact that nasal mucosal CD38 and other NADases may hydrolyze a portion of administered NAD+ before absorption, and that cellular uptake of intact NAD+ is limited by membrane impermeability — the species elevating intracellular NAD+ may be NMN or NR released by extracellular hydrolysis rather than intact NAD+.

Q: What is the recommended storage and in-use shelf life for NAD+ nasal spray, and why is it shorter than other formulations?

A: Sealed product should be stored at 2-8°C under an inert atmosphere, protected from light. Once first actuated, in-use shelf life is 14 days — shorter than stable peptide formulations (28 days) due to the hydrolytic instability of the glycosidic bond linking the nicotinamide ring to the ribose in aqueous solution, which accelerates at pH outside the 6.5-7.4 stability window or at elevated temperature. DO NOT FREEZE. Monitor solution integrity by UV absorbance (A260/A340 ratio) before each research use.

Q: How does NAD+ differ from NMN, NR, and other NAD+ precursors supplied at RCDbio?

A: NAD+ (CAS 53-84-9; MW 664.4 g/mol) is the dinucleotide coenzyme itself — the active species consumed by sirtuins, PARPs, and CD38 during catalysis. NMN (CAS 1094-61-7; MW 334.22 g/mol) and NR (CAS 1341-23-7; MW 255.25 g/mol) are smaller precursor molecules that enter cells via specific transporters and are enzymatically converted to NAD+ intracellularly via the salvage pathway. Direct exogenous NAD+ has limited cell membrane permeability; its intracellular effect may depend on extracellular hydrolysis to precursor species. Researchers should specify which form is required for their assay — direct NAD+ is the appropriate substrate for enzyme activity assays (sirtuin, PARP), while NMN or NR are more appropriate for cellular NAD+ repletion experiments requiring intracellular NAD+ elevation.

Q: Is the NAD+ nasal spray formulation suitable for cell culture or in vitro assay systems?

A: The formulation is prepared in sterile PBS (pH 6.5-7.4) without preservatives, compatible with standard cell culture pH ranges. Dilution into culture medium before application is recommended to normalize osmolarity. NAD+ is the direct substrate for sirtuin, and PARP enzyme activity assays in cell-free systems, and can be added at defined concentrations for Km and Vmax characterization. For cellular NAD+ repletion studies, researchers should account for membrane impermeability to intact NAD+ and the potential role of extracellular CD38-mediated hydrolysis in culture systems. Verify solution integrity by UV absorbance before each assay. Researchers are responsible for confirming compatibility.

Q: What is the WADA status of NAD+?

A: NAD+ is not explicitly named on the 2026 WADA Prohibited List. As an endogenous coenzyme universally present in all mammalian cells, it does not fall within the currently named prohibited substance categories. However, WADA’s S0 category may apply to research-labeled formulations of NAD+ in competitive sports contexts. Researchers operating within WADA Code jurisdictions should verify current status at GlobalDRO.com. RCDbio products are supplied for laboratory research purposes only.

Q: What is the FDA regulatory status of NAD+ nasal spray?

A: No FDA-approved pharmaceutical product for intranasal NAD+ administration exists. NAD+ is not currently listed on the FDA 503A bulk drug substance Category 1 or Category 2 lists as of June 2026. The research-grade nasal spray supplied by RCDbio is not a pharmaceutical product, is not a dietary supplement, and is not equivalent to any compounded or approved formulation. It is supplied exclusively for in vitro and preclinical laboratory research purposes.

Q: Why is NAD+ considered unique compared to other compounds in the RCDbio nasal spray range?

A: NAD+ is the only non-peptide compound in the RCDbio nasal spray research range. As a dinucleotide coenzyme, it has no amino acid sequence, no DPP-IV susceptibility, and no receptor agonist mechanism. Its biological activity operates via two distinct modes: cycling redox cofactor function (NAD+/NADH) and consumed co-substrate function for sirtuins, PARPs, and CD38. Its delivery pharmacology differs fundamentally from peptides in this range: nasal mucosal NADase activity (CD38, SARM1) actively degrades administered NAD+; cellular uptake of intact NAD+ is limited by membrane impermeability; and the intracellular NAD+-elevating effect may be mediated by precursor metabolites (NMN, NR) produced by extracellular hydrolysis rather than intact NAD+ absorption.

Related Research Compounds

Researchers investigating NAD+ nasal spray may also be interested in the following compounds currently available for laboratory research at RCDbio:

MOTS-c Nasal Spray — A mitochondrial-derived peptide investigated for AMPK-mediated metabolic homeostasis and antioxidant response element (ARE) gene regulation; shares the mitochondrial bioenergetics and cellular energy metabolism research context.

Epithalon Nasal Spray — A synthetic tetrapeptide investigated for telomerase modulation, neuroendocrine signaling, and longevity-associated pathway research; shares the aging biology and CNS neuroprotection research context.

Reduced Glutathione (GSH) Nasal Spray — The primary intracellular antioxidant and redox buffer; complementary to NAD+ in cellular oxidative stress and redox biology research via non-overlapping antioxidant mechanisms.

All products listed are for laboratory and research purposes only.

References

1. Griffiths, H.B.S., Williams, C., King, S.J., & Allison, S.J. (2020). Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target. Biochemical Society Transactions, 48(3), 733-744.

   https://pubmed.ncbi.nlm.nih.gov/32573651/

   DOI: https://doi.org/10.1042/BST20190033

2. Stromland, O., Diab, J., Ferrario, E., Sverkeli, L.J., & Ziegler, M. (2021). The balance between NAD+ biosynthesis and consumption in ageing. Mechanisms of Ageing and Development, 199, 111569.

   https://pubmed.ncbi.nlm.nih.gov/34509469/

   DOI: https://doi.org/10.1016/j.mad.2021.111569

3. Braidy, N., Berg, J., Clement, J., Khorshidi, F., Poljak, A., Jayasena, T., Grant, R., & Sachdev, P. (2018). Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related degenerative diseases: rationale, biochemistry, pharmacokinetics, and outcomes. Antioxidants and Redox Signaling, 30(2), 251-294.

   https://pubmed.ncbi.nlm.nih.gov/29634344/

   DOI: https://doi.org/10.1089/ars.2017.7269

4. Wong, C.Y.J., Baldelli, A., Hoyos, C.M., et al. (2024). Insulin delivery to the brain via the nasal route: unraveling the potential for Alzheimer’s Disease therapy. Drug Delivery and Translational Research, 14(7), 1776-1793.

   https://pubmed.ncbi.nlm.nih.gov/38441832/

Research Transparency Note: References 1, 2, and 3 are peer-reviewed biochemical and pharmacological reviews of NAD+ biology characterizing its roles in cellular energy metabolism, DNA repair, sirtuin-mediated epigenetic regulation, and age-associated disease — all in cell and animal model systems or human biochemistry data. None characterizes intranasal NAD+ delivery specifically. Reference 4 provides class-level intranasal delivery evidence for small molecules in rodent model preparations. No published peer-reviewed study has formally characterized the pharmacokinetics, CNS bioavailability, or biological activity of intranasal NAD+ nasal spray as of June 2026. NAD+ is the only non-peptide compound in the RCDbio nasal spray research range; its delivery pharmacology, stability at the nasal mucosa, and mechanism of cellular action differ fundamentally from peptide compounds in this series, and these differences are disclosed throughout this document.

Disclaimer

NAD+ (Nicotinamide Adenine Dinucleotide) Nasal Spray is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co